

Restriction map of pAcGFP1-Golgi Vector. Restriction sites in bold are unique.

Description

pAcGFP1-Golgi Vector encodes a fusion protein consisting of the N-terminal 81 amino acids of the human beta 1,4-galactosyltransferase (GT; 1) directly upstream of the green fluorescent protein (GFP) from *Aequorea coerulescens* (AcGFP1). The human beta 1,4-galactosyltransferase sequence contains a membrane-anchoring signal peptide that targets the protein to the transmedial region of the Golgi aparatus (2–4). AcGFP1 (excitation maximum = 475 nm; emission maximum = 505 nm) contains silent mutations that create an open reading frame comprised almost entirely of optimized human codons. These changes increase the translational efficiency of the AcGFP1 mRNA and, consequently, the expression of AcGFP1 in mammalian and plant cells.

SV40 polyadenylation signals downstream of the protein coding region direct proper processing of the 3' end of the mRNA. The vector contains an SV40 origin for replication and a neomycin resistance (Neo^r) gene for selection (using G418) in eukaryotic cells (5). A bacterial promoter (*P*) upstream of Neo^r expresses kanamycin resistance in *E. coli*. The vector backbone also provides a pUC origin of replication for propagation in *E. coli* and an f1 origin for single-stranded DNA production.

Use

(PR49771; published 17 September 2004)

pAcGFP1-Golgi Vector is designed for fluorescent labeling of the Golgi apparatus. pAcGFP1-Golgi can be introduced into mammalian cells using any standard transfection method. If required, stable transformants can be selected using G418 (5). pAcGFP1-Golgi is not intended as a cloning vector; however, the backbone does contain unique restriction sites upstream and downstream of the AcGFP1-Golgi sequence which permit its excision.

United States/Canada

Clon**tech**

Clontech Laboratories, Inc. ATakara Bio Company 1290 Terra Bella Ave. Mountain View, CA 94043 Technical Support (US) E-mail: tech@clontech.com www.clontech.com

Location of features

- Human cytomegalovirus (CMV) immediate early promoter: 1–589 Enhancer region: 59–465; TATA box: 554–560; transcription start point: 583 C→G mutation to remove Sac I site: 569
- Human beta 1,4-GT-AcGFP1 fusion Start codon: 597–599
 N-terminal 81 a. a. of human beta 1,4-GT: 597–842 Start of AcGFP1 coding sequences (ATG): 858–1574 Insertion of Val at position 2: 861–863 Stop codon: 1575–1577
- SV40 early mRNA polyadenylation signal Polyadenylation signals: 1730–1735 & 1759–1764; mRNA 3' ends: 1768 & 1780
- f1 single-strand DNA origin: 1827–2282 (packages the noncoding strand of AcGFP1-Golgi)
- Bacterial promoter for expression of Kan^r gene.
 –35 region: 2344–2349; –10 region: 2367–2372; Transcription start point: 2379
- SV40 origin of replication: 2623-2758
- SV40 early promoter Enhancer (72-bp tandem repeats): 2456–2527, 2528–2599 21-bp repeats: 2603–2623, 2624–2644 & 2646–2666 Early promoter element: 2679–2685 Major transcription start points: 2675, 2713, 2719 & 2724
- Kanamycin/neomycin resistance gene Neomycin phosphotransferase coding sequences: Start codon (ATG): 2807–2809; stop codon: 3599–3601 G→A mutation to remove *Pst* I site: 2989 C→A (Arg to Ser) mutation to remove *Bss*H II site: 3335
- Herpes simplex virus (HSV) thymidine kinase (TK) polyadenylation signal Polyadenylation signals: 3837–3842 & 3850–3855
- pUC plasmid replication origin: 4186-4829

Propagation in *E. coli*

- Suitable host strains: Fusion-Blue[™] competent cells (Cat. No. 636700), DH5α, HB101, and other general purpose strains. Single-stranded DNA production requires a host such as JM109 or XL1-Blue that contains an F plasmid.
- Selectable marker: plasmid confers resistance to kanamycin (50 µg/ml) in *E. coli* hosts.
- E. coli replication origin: pUC
- Copy number: ≈500
- Plasmid incompatibility group: pMB1/CoIE1

References

- 1. Watzele, G. & Berger, E. G. (1990) Nucleic Acids. Res. 18:7174.
- 2. Llopis, J., et al. (1998) Proc. Natl. Acad. Sci. USA 95:6803–6808.
- Yamaguchi, N. & Fukuda, M. N. (1995) J. Biol. Chem. 270:12170–12176.
 Gleeson, P. A., et al. (1994) Glycoconjugate J. 11:381–394.
- 5. Gorman, C. (1985) In DNA Cloning: A Practical Approach, Vol. II, Ed. Glover, D. M. (IRL Press, Oxford, UK), pp. 143–190.

Note: The attached sequence file has been compiled from information in the sequence databases, published literature, and other sources, together with partial sequences obtained by Clontech Laboratories, Inc. This vector has not been completely sequenced.

Notice to Purchaser

This product is intended to be used for research purposes only. It is not to be used for drug or diagnostic purposes, nor is it intended for human use. Clontech products may not be resold, modified for resale, or used to manufacture commercial products without written approval of Clontech Laboratories, Inc.

Not-For-Profit Entities: Orders may be placed in the normal manner by contacting your local representative or Clontech Customer Service at 650.919.7300. At its discretion, Clontech grants Not-For-Profit Entities a non-exclusive, royalty-free, personal, limited license to use this product for non-commercial life science research use only. Such license specifically excludes the right to sell or otherwise transfer this product, its components or derivatives thereof to third parties. No modifications to the protein coding sequence may be made without express written permission from Clontech. Any other use of this product requires a license from Clontech. For license information, please contact a licensing representative by phone at 650.919.7320 or by e-mail at licensing@clontech.com.

For-Profit Entities wishing to use this product are required to obtain a license from Clontech. For license information, please contact a licensing representative by phone at 650.919.7320 or by e-mail at licensing@clontech.com

This product is the subject of pending U.S. patents.

DH5 α^{TM} is a trademark of Invitrogen Corporation.

Clontech, Clontech logo and all other trademarks are the property of Clontech Laboratories, Inc. Clontech is a Takara Bio Company. @2005